A folded and immunogenic IgE-hyporeactive variant of the major allergen Phl p 1 produced in Escherichia coli.
Author
Summary, in English
Group 1 grass pollen allergens are a major cause of allergic disease. Specific immunotherapy involving controlled administration of allergens can be used as a disease-modifying treatment for such disease. Recombinant allergen variants with reduced IgE binding capacity may be used as component in such vaccines, as they may induce fewer treatment side effects than materials currently in use. A mutated variant of the immunodominant C-terminal domain of the group 1 grass pollen allergen Phl p 1 was recently established through an approach that used a set of human monoclonal IgE as a guide to identify mutations that disturbed IgE-allergen interactions. Further analysis of this domain is required to establish its potential for use in treatment.
Publishing year
2015
Language
English
Publication/Series
BMC Biotechnology
Volume
15
Document type
Journal article
Publisher
BioMed Central (BMC)
Topic
- Respiratory Medicine and Allergy
Status
Published
Project
- Human IgE repertoires and an anti-allergome resource
Research group
- Microbiology Group
ISBN/ISSN/Other
- ISSN: 1472-6750